Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial-Reference-Cited by-同舟云学术

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

Published:2008-11 Issue:11 Volume:9 Page:1058-1068
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Denham James W,Steigler Allison,Wilcox Chantelle,Lamb David S,Joseph David,Atkinson Chris,Matthews John,Tai Keen-Hun,Spry Nigel A,Christie David,Gleeson Paul S,Greer Peter B,D'Este Catherine

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy;D'Amico;J Natl Cancer Inst,2003

2. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases;Partin;Urology,1994

3. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation;Albertsen;J Urol,2004

4. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy;Zhou;J Clin Oncol,2005

5. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy;Freedland;JAMA,2005

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review;European Urology;2024-09

2. Predictive Value of the Prostate-Specific Antigen Doubling Time for the Effectiveness of Metastasis-Directed Radiotherapy in Patients with Oligometastases after Radical Treatment for Non-metastatic Prostate Cancer: A Single Institution Retrospective Study;2024-03-19

3. Multiparametric Magnetic Resonance Imaging– Guided Dose-Escalated Radiation Therapy for Localized Prostate Cancer: A Prospective Phase 2 Trial;Practical Radiation Oncology;2023-11

4. Risk of Short-Term Prostate-Specific Antigen Recurrence and Failure in Patients With Prostate Cancer;JAMA Network Open;2023-10-06

5. Long non-coding RNA ENST00000503625 is a potential prognostic biomarker and metastasis suppressor gene in prostate cancer;Journal of Cancer Research and Clinical Oncology;2023-03-15